A biomarker driven global phase 3 clinical trial of DB102 as a first line therapy for diffuse large B-cell lymphoma (DLBCL) patients.
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Enzastaurin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Biomarker; Therapeutic Use
- 20 Feb 2017 New trial record
- 16 Feb 2017 According to a Denovo Biopharma media release, compnay has submitted the IND application to the China FDA and anticipates initiating this trial in 2017.